Overview

Study of VI-0521 Compared to Placebo in Treatment of Obesity in Adults

Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of two doses of VI-0521 compared to placebo in treatment of obesity in an adult population with BMI ≥ 35.
Phase:
Phase 3
Details
Lead Sponsor:
VIVUS, Inc.
Collaborator:
Medpace, Inc.
Treatments:
Phentermine
Topiramate